Mirabegron Glenmark

Mirabegron, the active ingredient in Mirabegron Glenmark, is a β3‑adrenergic receptor agonist presented as a tablet for oral use. It treats overactive bladder symptoms such as urgency, frequency and urge incontinence in adults.

GNH USA supplies Mirabegron Glenmark as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mirabegron is used to manage disorders of bladder storage that involve detrusor overactivity.

Overactive bladder: improves bladder capacity and reduces urgency episodes Urinary urgency: lessens the frequency of sudden urges to void Urinary frequency: decreases daytime voiding episodes Urge urinary incontinence: reduces episodes of involuntary leakage

Common Side Effects: - Hypertension: mild to moderate increase in blood pressure - Nasopharyngitis: inflammation of the nasal passages and throat - Headache: transient pain in the head region - Constipation: reduced bowel motility leading to hard stools

Serious or Rare Side Effects: - Severe hypertension: marked elevation of blood pressure requiring medical attention - Urinary retention: inability to empty the bladder fully - Tachycardia: rapid heart rate that may be symptomatic - Angioedema: swelling of deep skin layers, potentially airway‑compromising - Anaphylaxis: severe allergic reaction with systemic involvement

Before initiating therapy, consider the following precautions.

Monitor blood pressure: check regularly as Mirabegron may raise systolic values Assess renal function: dose adjustment may be needed in severe impairment Review cardiovascular status: use caution in patients with arrhythmias Avoid in uncontrolled hypertension: contraindicated when blood pressure is not controlled Store at ambient temperature: keep below 25°C, in the original pack, and protect from moisture

Mirabegron can affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine): may increase Mirabegron exposure - Strong CYP3A4 inhibitors (e.g., ketoconazole): can raise plasma levels - Antihypertensive agents: may reduce their efficacy - Monoamine oxidase inhibitors: risk of hypertensive crisis

Moderate Interactions (Monitor Closely): - CYP2D6 substrates (e.g., metoprolol): monitor for increased effects - CYP3A4 substrates (e.g., midazolam): observe for enhanced sedation - Diuretics: watch electrolyte balance and volume status